false
0001867066
0001867066
2023-11-07
2023-11-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 7, 2023
Journey Medical Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware | |
001-41063 | |
47-1879539 |
(State or Other Jurisdiction of Incorporation) | |
(Commission File Number) | |
(IRS
Employer Identification No.) |
9237 E Via de Ventura Blvd., Suite 105
Scottsdale, AZ 85258
(Address of Principal Executive Offices)
(480) 434-6670
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act.
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act.
¨ Pre-commencement communications
pursuant to Rule 14d-2b under the Exchange Act.
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
DERM |
Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter). x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. | Results of Operations and Financial Condition. |
On November 7, 2023,
Journey Medical Corporation (the “Company” or “Journey”) issued a press release to provide a corporate update
and to announce its financial results for the three months ended September 30, 2023. A copy of such press release is being furnished as
Exhibit 99.1 to this report.
The information, including
Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not
be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set
forth by specific reference in such filing.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Journey Medical Corporation |
|
(Registrant) |
Date: November 7, 2023 |
|
|
By: |
/s/ Claude Maraoui |
|
|
Claude Maraoui |
|
|
Chief Executive Officer, President and Director |
Exhibit 99.1
Journey Medical Corporation
Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Company generated total net
revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023
GAAP net income increased
to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023, compared to a GAAP net loss of
$10.1 million, or $0.57 per share basic and diluted for the third quarter of 2022
Received
an upfront payment of $19.0 million upon entering into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza® in South
Korea and other Asian nations
New Drug Application
for DFD-29 expected to be submitted to FDA around the end of 2023
Company to hold conference call
today at 4:30 p.m. ET
Scottsdale, AZ - November 7, 2023
- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical
company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription
pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights
for the third quarter ended September 30, 2023.
Claude Maraoui, Journey Medical’s
Co-Founder, President and Chief Executive Officer, said, “In the third quarter of 2023, our total net revenues, which included the
Maruho Co., Ltd. (“Maruho”) out-licensing upfront payment, were $34.5 million, a 101% increase from $17.2 million in the second
quarter, and a 114% increase from $16.1 million in the third quarter of 2022. We are also extremely pleased with the positive topline
results from our two Phase 3 clinical trials evaluating DFD-29 for the treatment of rosacea. We expect to submit a New Drug Application
(“NDA”) to the FDA for DFD-29 around year-end.”
Financial Results:
| · | Total net revenues in the third quarter of 2023 were $34.5 million, an increase of $18.4 million, or 114%, compared to the third quarter
of 2022. The increase is due to the Company’s entry into a new license agreement with Maruho resulting in $19.0 million of revenue
during the third quarter. |
| · | Cost of goods sold decreased by $0.8 million, or 11%, to $6.4 million for the three-month period ended September 30, 2023, from $7.2
million for the three-month period ended September 30, 2022. The decrease is primarily due to the contractual reduction in our Qbrexza®
royalty from period-to-period. |
| · | Selling, general and administrative expenses (“SG&A”) decreased by $7.0 million, or 45%,
to $8.6 million for the third quarter of 2023, from $15.6 million for the third quarter 2022. The decrease is mainly attributable to the
Company’s expense reduction efforts, primarily in sales and marketing and other SG&A areas. The impact of the cost reduction
initiatives is expected to result in a reduction of greater than $17.0 million of annual SG&A expenses in 2023, surpassing our earlier
target of $12.0 million. |
| · | Research and Development (“R&D”) expenses decreased by $0.6 million, or 21%, to $2.2
million for the third quarter of 2023, from $2.8 million for the third quarter 2022. The decrease is related to lower clinical trial expenses
to develop our DFD-29 product, as the two Phase 3 studies have concluded. |
| · | GAAP net income was $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third
quarter of 2023, compared to GAAP net loss of $(10.1) million, or $(0.57) per share basic and diluted, for the third quarter of 2022. |
| · | The Company’s non-GAAP results in the table below reflect Adjusted EBITDA of $20.8 million, or
$1.13 per share basic and $0.99 per share diluted, for the third quarter of 2023, compared to Adjusted EBITDA of $(4.0 million), or $(0.23)
per share basic and diluted for the third quarter of 2022. Adjusted EBITDA and Adjusted EBITDA per share basic and diluted are non-GAAP
financial measures, each of which are reconciled to the most directly comparable financial measures calculated in accordance with GAAP
below under “Use of Non-GAAP Measures.” |
| · | At September 30, 2023, the Company had $24.8 million in cash and cash equivalents, compared to $32.0 million in cash and cash equivalents
as of December 31, 2022. |
| · | In July 2023, the Company voluntarily repaid the entire $10.0 million outstanding term loan. The repayment satisfied all of the Company’s
outstanding debt obligations under its debt facility. The Company therefore has no further debt obligations. |
Recent Corporate Highlights:
| · | The Company is pleased to announce results from the Phase 3 studies (MVOR-1 & MVOR-2) for DFD-29 on a secondary endpoint related
to erythema (redness) assessment. DFD-29 showed significantly superior reduction in Clinicians Erythema Assessment (CEA) compared to placebo
in both MVOR-1 and MVOR-2 clinical trials. Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical, said,
“Erythema is an important sign of rosacea severity and the beneficial effect of DFD-29 on erythema is very relevant to rosacea treatment.
Also, erythema improvement is likely to be a significant differentiator for DFD-29 over the current standard of care.” |
CEA Results from
MVOR-1 and MVOR-2
Proportion of Subjects with at Least a 2-Grade Reduction in CEA |
STUDY |
DFD-29 (40 mg) |
Placebo |
Difference (95% CI) |
P-values |
MVOR-1 |
39/122 (31.7%) |
11/80 (13.8%) |
18.1% (7.32%, 28.96%) |
0.006 |
MVOR-2 |
30/123 (24.5%) |
10/82 (12%) |
13.9% (3.71%, 23.99%) |
0.023 |
| · | In October 2023, Journey Medical had a productive pre-NDA meeting with the FDA for DFD-29 (Minocycline
Hydrochloride Modified Release Capsules, 40 mg) to treat rosacea in adults. The Company expects to provide an update following receipt
of the meeting minutes. |
| · | In October 2023, Journey Medical announced data from a comparative bioavailability (bridging) study of
DFD-29 (40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg), which were presented at the 43rd Annual
Fall Clinical Dermatology Conference. The data demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105
mg), and no significant safety issues were noted for DFD-29. |
| · | In September 2023, Journey Medical entered into an exclusive license agreement with Maruho, a Japanese
company specializing in dermatology as well as Journey Medical’s exclusive licensing partner that developed and is commercializing
Qbrexza® (Rapifort®) in Japan. Under the terms of the Agreement, Journey Medical received a $19.0 million nonrefundable upfront
payment and granted Maruho an exclusive license to develop and commercialize Qbrexza (Rapifort / DRM04 / glycopyrronium tosylate hydrate)
for the treatment of hyperhidrosis in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam,
Brunei, Cambodia, Myanmar and Laos (the “Territory”). Maruho is responsible for all development and commercialization costs
for the program throughout the Territory. |
| · | In July 2023, Journey Medical announced positive topline data from its two DFD-29 Phase 3 clinical trials for the treatment of rosacea.
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant
safety issues. DFD-29 demonstrated statistical superiority over both the standard of care Oracea® and placebo for Investigator’s
Global Assessment treatment success and the reduction in the total inflammatory lesion count in both studies. Journey Medical plans to
file an NDA to the FDA for DFD-29 around the end of 2023 and anticipates potential approval from the FDA in the fourth quarter of 2024. |
Conference Call and Webcast Information
Journey Medical management will conduct a conference call and
audio webcast on Tuesday, November 7, 2023, at 4:30 p.m. ET.
To listen to the conference call, interested
parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317- 5413 (international). All callers should dial in approximately
10 minutes prior to the scheduled start time and ask to be joined into the Journey Medical conference call. Participants can register
for the conference here: https://dpregister.com/sreg/10183424/fab4c8de00. Please
note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on
the News and Events page of the Investors section of Journey Medical’s website,
www.journeymedicalcorp.com,
and will remain available for replay for approximately 30 days after the meeting.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey
Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug
Administration-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales
and marketing model. The company currently markets eight branded and two generic products that help treat and heal common skin conditions.
The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s
most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq:
FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic
reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com.
Forward-Looking Statements
This press release may contain
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the
Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but
are not limited to, any statements relating to our growth strategy and product development programs and any other statements that
are not historical facts. The words “anticipate,” “believe,” “estimate,” “may,”
“expect,” “will,” “could,” “project,” “intend,” “potential”
and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on
management’s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those
currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation
and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales
derive from products that may become subject to third- party generic competition, the introduction of new competitor products, or an
increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating
income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative
or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any
setback relating to the sale of such products could impair our operating results; competition could limit our products’
commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk
that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties
for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and
integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our
ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29
product candidate and any future product candidates that we may develop, in-license or acquire; clinical drug development is very
expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our
current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours;
risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection
for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks,
or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going
concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;
our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental
to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on
Form 10-K for the year ended December 31, 2022, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We
expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements
contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such
statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Company Contact:
Jaclyn Jaffe (781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros 6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
JOURNEY MEDICAL CORPORATION
Unaudited Condensed Consolidated
Balance Sheets
($ in thousands except for share
and per share amounts)
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
ASSETS | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 24,749 | | |
$ | 32,003 | |
Accounts receivable, net of reserves | |
| 7,989 | | |
| 28,208 | |
Inventory | |
| 11,024 | | |
| 14,159 | |
Prepaid expenses and other current assets | |
| 924 | | |
| 3,309 | |
Total current assets | |
| 44,686 | | |
| 77,679 | |
| |
| | | |
| | |
Intangible assets, net | |
| 21,102 | | |
| 27,197 | |
Operating lease right-of-use asset, net | |
| 124 | | |
| 189 | |
Other assets | |
| 6 | | |
| 95 | |
Total assets | |
$ | 65,918 | | |
$ | 105,160 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 28,164 | | |
$ | 36,570 | |
Due to related party | |
| 1,093 | | |
| 413 | |
Accrued expenses | |
| 16,026 | | |
| 19,388 | |
Accrued interest | |
| - | | |
| 160 | |
Income taxes payable | |
| 130 | | |
| 35 | |
Line of credit | |
| - | | |
| 2,948 | |
Deferred cash payment (net of discount of $9) | |
| - | | |
| 4,991 | |
Installment payments – licenses, short-term | |
| 3,000 | | |
| 2,244 | |
Operating lease liability, short-term | |
| 97 | | |
| 83 | |
Total current liabilities | |
| 48,510 | | |
| 66,832 | |
| |
| | | |
| | |
Term loan, long-term (net of debt discount of $174) | |
| - | | |
| 19,826 | |
Installment payments – licenses, long-term | |
| - | | |
| 1,412 | |
Operating lease liability, long-term | |
| 34 | | |
| 108 | |
Total liabilities | |
| 48,544 | | |
| 88,178 | |
| |
| | | |
| | |
Stockholders' equity | |
| | | |
| | |
Common stock, $.0001 par value, 50,000,000 shares authorized, 12,496,782 and 11,765,700 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | |
| 1 | | |
| 1 | |
Common stock - Class A, $.0001 par value, 50,000,000 shares authorized, 6,000,000 shares issued and outstanding as of September 30, 2023 and December 31, 2022 | |
| 1 | | |
| 1 | |
Additional paid-in capital | |
| 87,584 | | |
| 85,482 | |
Accumulated deficit | |
| (70,212 | ) | |
| (68,502 | ) |
Total stockholders' equity | |
| 17,374 | | |
| 16,982 | |
Total liabilities and stockholders' equity | |
$ | 65,918 | | |
$ | 105,160 | |
JOURNEY MEDICAL CORPORATION
Unaudited Condensed Consolidated
Statements of Operations
($ in thousands except for share
and per share amounts)
| |
Three-Month Periods Ended | | |
Nine-Month Periods Ended | |
​ | |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue: | |
​ | | |
​ | | |
​ | | |
​ | |
Product revenue, net | |
$ | 15,279 | | |
$ | 16,043 | | |
$ | 44,405 | | |
$ | 55,074 | |
Other revenue | |
| 19,260 | | |
| 73 | | |
| 19,519 | | |
| 2,629 | |
Total revenue | |
| 34,539 | | |
| 16,116 | | |
| 63,924 | | |
| 57,703 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| ​ | | |
| ​ | | |
| ​ | | |
| ​ | |
Cost of goods sold – product revenue | |
| 6,429 | | |
| 7,221 | | |
| 20,645 | | |
| 23,057 | |
Research and development | |
| 2,229 | | |
| 2,812 | | |
| 6,036 | | |
| 6,687 | |
Selling, general and administrative | |
| 8,636 | | |
| 15,575 | | |
| 34,069 | | |
| 45,481 | |
Loss on impairment of intangible assets | |
| - | | |
| - | | |
| 3,143 | | |
| - | |
Total operating expenses | |
| 17,294 | | |
| 25,608 | | |
| 63,893 | | |
| 75,225 | |
Income (loss) from operations | |
| 17,245 | | |
| (9,492 | ) | |
| 31 | | |
| (17,522 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other expense (income) | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| (8 | ) | |
| (3 | ) | |
| (209 | ) | |
| (10 | ) |
Interest expense | |
| 268 | | |
| 559 | | |
| 1,674 | | |
| 1,402 | |
Foreign exchange transaction losses | |
| 101 | | |
| 22 | | |
| 181 | | |
| 22 | |
Total other expense (income) | |
| 361 | | |
| 578 | | |
| 1,646 | | |
| 1,414 | |
Income (loss) before income taxes | |
| 16,884 | | |
| (10,070 | ) | |
| (1,615 | ) | |
| (18,936 | ) |
| |
| | | |
| | | |
| | | |
| | |
Income tax expense | |
| 95 | | |
| 10 | | |
| 95 | | |
| 50 | |
Net income (loss) | |
$ | 16,789 | | |
$ | (10,080 | ) | |
$ | (1,710 | ) | |
$ | (18,986 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) per common share: | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | 0.91 | | |
$ | (0.57 | ) | |
$ | (0.09 | ) | |
$ | (1.09 | ) |
Diluted | |
| 0.80 | | |
| (0.57 | ) | |
| (0.09 | ) | |
| (1.09 | ) |
Weighted average number of common shares: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 18,416,368 | | |
| 17,618,064 | | |
| 18,078,437 | | |
| 17,464,561 | |
Diluted | |
| 21,034,758 | | |
| 17,618,064 | | |
| 18,078,437 | | |
| 17,464,561 | |
The weighted average number of common shares Basic
in the above table is used to calculate both basic and diluted loss per share for the three and nine-month periods ended September 30,
2022, and basic and diluted loss per share for the nine-month period ended September 30, 2023, as the net loss for these periods is antidilutive
and the effect would be to reduce the loss per share.
Use of Non-GAAP Measures:
In addition to the GAAP financial
measures, the Company has, in this press release, included certain non-GAAP measurements, including Adjusted EBITDA, Adjusted EBITDA per
share basic and Adjusted EBITDA per share diluted. We define Adjusted EBITDA as net income (loss) excluding interest, taxes and depreciation,
less certain other non-cash and infrequent items not considered to be normal, recurring operating expenses, including, share-based compensation
expense, amortization and impairment of acquired intangible assets, inventory step-ups from the purchases of intangibles assets and products,
severance, non-core research and development expense and foreign exchange transaction losses. In particular, we exclude the following
matters for the reasons more fully described below:
| · | Share-Based Compensation Expense: We exclude share-based compensation from our adjusted financial results because share-based
compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our
stock price on the dates share-based grants are issued. |
| · | Non-core and Short-term Research and Development Expense: We exclude research and development costs incurred in connection
with our DFD-29 product candidate, which is the only product in our portfolio not currently approved for marketing and sale, because we
do not consider such costs to be normal, recurring operating expenses that are core to our long-term strategy. Instead, our long-term
strategy is focused on the marketing and sale of acquired and/or licensed FDA-approved dermatological products. |
| · | Amortization and impairments of Acquired Intangible assets: We exclude the impact of certain amounts
recorded in connection with the acquisitions of intangible assets that are either non-cash or not normal, recurring operating expenses
due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. These amounts may include non-cash
items such as the amortization of acquired intangible assets, impairments and amortization of step-ups of acquisition accounting adjustments
to inventories. |
Adjusted EBITDA per share basic and
Adjusted EBITDA per share diluted are determined by dividing the resulting Adjusted EBITDA by the number of shares outstanding on an actual
and fully diluted basis.
Management believes use of these non-GAAP
measures provide meaningful supplemental information regarding the Company’s performance because (i) it allows for greater transparency
with respect to key measures used by management in its financial and operational decision-making, (ii) it excludes the impact of non-cash
or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that
may obscure trends in the Company’s core operating performance and (iii) it is used by institutional investors and the analyst community
to help analyze the Company's results. However, Adjusted EBITDA, Adjusted EBITDA per share basic, Adjusted EBITDA per share diluted and
any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding
measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the manner in which they are
calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies,
including the Company’s competitors.
The table below provides a reconciliation
from GAAP to non-GAAP measures:
JOURNEY MEDICAL CORPORATION
Reconciliation of GAAP to
Non-GAAP Adjusted EBITDA
($ in thousands except for share
and per share amounts)
| |
Three-month periods ended
September 30, | | |
Nine-month periods ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
GAAP Net Income (Loss) | |
$ | 16,789 | | |
$ | (10,080 | ) | |
$ | (1,710 | ) | |
$ | (18,986 | ) |
| |
| | | |
| | | |
| | | |
| | |
EBITDA: | |
| | | |
| | | |
| | | |
| | |
Interest | |
| 260 | | |
| 556 | | |
| 1,465 | | |
| 1,392 | |
Taxes | |
| 95 | | |
| 10 | | |
| 95 | | |
| 50 | |
Depreciation | |
| - | | |
| - | | |
| - | | |
| | |
Amortization of acquired intangible assets | |
| 814 | | |
| 1,016 | | |
| 2,952 | | |
| 3,050 | |
EBITDA | |
| 17,958 | | |
| (8,498 | ) | |
| 2,802 | | |
| (14,494 | ) |
| |
| | | |
| | | |
| | | |
| | |
Non-GAAP Adjusted EBITDA: | |
| | | |
| | | |
| | | |
| | |
Share-based compensation | |
| 558 | | |
| 1,438 | | |
| 2,077 | | |
| 2,985 | |
Loss on impairment of intangible assets | |
| - | | |
| - | | |
| 3,143 | | |
| - | |
Inventory step-up expense | |
| - | | |
| 214 | | |
| - | | |
| 525 | |
Non-core & short-term R&D | |
| 2,206 | | |
| 2,778 | | |
| 5,949 | | |
| 6,653 | |
Foreign exchange transaction losses | |
| 100 | | |
| 22 | | |
| 181 | | |
| 22 | |
Severance | |
| - | | |
| 27 | | |
| 711 | | |
| 27 | |
Non-GAAP Adjusted EBITDA | |
$ | 20,822 | | |
$ | (4,019 | ) | |
$ | 14,863 | | |
$ | (4,282 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) per common share: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| | | |
| | | |
| | | |
| | |
GAAP Net Income (Loss) | |
$ | 0.91 | | |
$ | (0.57 | ) | |
$ | (0.09 | ) | |
$ | (1.09 | ) |
Non-GAAP Net Income (Loss) | |
$ | 1.13 | | |
$ | (0.23 | ) | |
$ | 0.82 | | |
$ | (0.25 | ) |
Diluted | |
| | | |
| | | |
| | | |
| | |
GAAP Net Income (Loss) | |
$ | 0.80 | | |
$ | (0.57 | ) | |
$ | (0.09 | ) | |
$ | (1.09 | ) |
Non-GAAP Net Income (Loss) | |
$ | 0.99 | | |
$ | (0.23 | ) | |
$ | 0.72 | | |
$ | (0.25 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of common shares: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 18,416,368 | | |
| 17,618,064 | | |
| 18,078,437 | | |
| 17,464,561 | |
Diluted | |
| 21,034,758 | | |
| 17,618,064 | | |
| 20,588,661 | | |
| 17,464,561 | |
The weighted average number of common shares Basic
in the above table is used to calculate both GAAP and Non-GAAP basic and diluted loss per share for the three and nine-month periods ended
September 30, 2022, and GAAP basic and diluted loss per share for the nine-month period ended September 30, 2023, as the net loss for
these periods is antidilutive and the effect would be to reduce the loss per share.
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024